BERG, the clinical stage biopharmaceutical company that uses artificial intelligence (AI) to discover the biology of underlying disease, today announced results from a preclinical study of its investigational drug BPM 31510 (novel ubidecarenone formulation) in glioblastoma models. The study, presented as a poster at the Society for Neuroscience (SfN) Annual Meeting in Chicago, demonstrated a novel oxidative stress dependent mechanism of action of BPM 31510 associated with anti-cancer responses in Glioblastoma Multiforme (GBM).